Insulin Secretory Capacity and Insulin Resistance in Korean Type 2 Diabetes Mellitus Patients-Reference-Cited by-同舟云学术

Insulin Secretory Capacity and Insulin Resistance in Korean Type 2 Diabetes Mellitus Patients

Published:2016 Issue:3 Volume:31 Page:354
ISSN:2093-596X
Container-title:Endocrinology and Metabolism
language:en
Short-container-title:Endocrinol Metab

Author:

Kim Jong-Dai¹^ORCID,Lee Won-Young²^ORCID

Affiliation:

1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Konyang University Hospital, Konyang University College of Medicine, Daejeon, Korea.

2. Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

Publisher

Korean Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

http://synapse.koreamed.org/pdf/10.3803/EnM.2016.31.3.354

Reference37 articles.

1. From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

2. Slow Glucose Removal Rate and Hyperinsulinemia Precede the Development of Type II Diabetes in the Offspring of Diabetic Parents

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reference Standards for C-Peptide in Korean Population: A Korean Endocrine Hormone Reference Standard Data Center Study;Endocrinology and Metabolism;2024-06-30

2. Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective;Diabetes & Metabolism Journal;2024-05-31

3. Association of polygenic risk scores for insulin resistance risk and their interaction with a plant-based diet, especially fruits, vitamin C, and flavonoid intake, in Asian adults;Nutrition;2023-07

4. Triglyceride-Glucose Index Cutoff Point Is an Accurate Marker for Predicting the Prevalence of Metabolic Syndrome in Obese Caucasian Subjects;Annals of Nutrition and Metabolism;2022-10-07

5. A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study;Diabetes, Obesity and Metabolism;2022-06-09